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Objective: To examine the incidence of allergic rhinoconjunctivitis and asthma, and to assess
allergic rhinoconjunctivitis as a risk factor for incident asthma, we performed a 11-year follow-
up postal survey.
Methods: The original study population was a random population sample of 8000 inhabitants of
Helsinki aged 20e69 years in 1996. Participants in the first postal questionnaire survey, 6062
subjects, were invited to this follow-up study, and provided 4302 (78%) answers out of 5484
traced subjects in 2007.
Results: Cumulative incidence of asthma from 1996 to 2007 was 4.0% corresponding to an
annual incidence rate of 3.7/1000/year. After exclusion of those with asthma medication or
physician-diagnosed chronic bronchitis or COPD at baseline in 1996, the cumulative incidence
decreased to 3.5% (incidence rate 3.2/1000/year), and further to 2.7% (2.5/1000/year) when
also those reporting recurrent wheeze or shortness of breath during the last year in 1996 weretute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland. Tel.: þ358 50 5338809.
mnet.fi (P. Pallasaho).
1 Elsevier Ltd. All rights reserved.
1450 P. Pallasaho et al.omitted from the population at risk. Remission of asthma occurred in 43 subjects and was
16.9% over 11 years. Cumulative 11-year incidence of allergic rhinoconjunctivitis was 16.9%
corresponding to 16.8/1000/year, and cumulative remission was 18.1%. Incidence of allergic
rhinoconjunctivitis was significantly lower among those who had lived in the countryside or
on a farm during the first 5 years of life, but this was not true for asthma. In multivariate anal-
ysis, farm living during the first 5 years of life was protective for the development of allergic
rhinoconjunctivitis, OR 0.75 (95%CI 0.57e0.99). Allergic rhinoconjunctivitis was a significant
independent risk factor for incident asthma, OR 2.15 (95%CI 1.54e3.02). In the cohort, the
prevalence of rhinoconjunctivitis increased from 38.0% in 1996 to 40.9% in 2007, physician-
diagnosed asthma from 6.8% to 9.4%, while current smoking decreased from 31.3% to 23.3%.
Conclusion: Incidence of allergic rhinoconjunctivitis was higher than in earlier studies, while
asthma incidence remained on similar level, both being significantly higher in women. Allergic
rhinoconjunctivitis doubled the risk for incident asthma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
To respond to the increasing burden and costs due to
asthma in Finland, a national Asthma Programme was
conducted from 1994 to 2004.1 During this period, a further
increase occurred in prevalence of asthma and in use of
asthma medicines, but also a decrease in hospital days, and
disability pensions, as well as in costs per patient.1 Asthma
incidence increased in the 1990s,2,3 and the latest
measures of incidence of asthma among adults range from
2.1 to 2.5/1000 per year in Finland.4,5 A national Allergy
Programme launched in 2008 is aiming to reduce the burden
of allergic diseases including asthma and allergic rhino-
conjunctivitis by 2018.6
Studies of incidence of asthma are still scarce. Studies
by the Swedish Obstructive Lung Diseases in northern
Sweden (OLIN) reported a cumulative 10-year asthma inci-
dence of 3.2% among men and 4.5% among women from
1986 to 1996.7 After excluding those with symptoms
common in asthma and chronic bronchitis from the pop-
ulation at risk, the annual incidence for men was 1.7/1000
and for women 2.9/1000.7 The Swedish part of the Euro-
pean Community Respiratory Health Survey (ECHRS) from
1990 to 2000 and the Stockholm part of the FinEsS (Finland-
Estonia-Sweden) studies between 1996 and 2007 reported
similar results with a similar gender difference.8,9 The
average incidence of asthma was 2.2/1000/year in a pooled
analysis of the ECRHS from northern Europe.9 Data from the
ECRHS recently showed both non-allergic and allergic
rhinitis to be significant risk factors for incident asthma,
which was not true for atopy only.10 Remission of asthma
during a 10-year follow-up was 20% in the ECRHS from
northern Europe,11 and 15% in the FinEsS study from
Stockholm.8 In the OLIN studies, 5% of adult-onset asthma
was in remission after a mean follow-up of 6 years.12 Inci-
dence and remission of allergic rhinoconjunctivitis are less
studied than of asthma, although they often co-exist and
affect each others’ course.13
We performed an 11-year follow-up survey to assess the
incidence and remission of asthma and allergic rhino-
conjunctivitis in order to evaluate whether the earlier
increase in incidence of asthma has continued, and to
evaluate the impact of allergic rhinoconjunctivitis as a risk
factor for incident asthma.Material and methodsStudy population
This is a part of a large epidemiological study, which has
been in progress in Finland, Estonia, and Sweden (FinEsS)
since 1996. The original study population comprised
subjects obtained at random from the population registers
to represent the general population. The original study
population in Helsinki, Finland, included 8000 subjects aged
20e69 years, and 6062 (76%) subjects participated in the
first postal questionnaire in 1996.14 A follow-up study was
performed in 2007, and 5484 subjects could be traced out
of the original 6062 participants, with the 4302 complete
answers obtained giving a response rate of 78% (Table 1). Of
the 578 subjects lost to follow-up, 336 were dead, 8 were
living abroad, 64 were traced without access to address,
and 170 could not be traced. The studies were approved by
the ethics committee of Helsinki University Hospital.
Questionnaire
Our self-administered postal questionnaire14 with two
reminders was originally developed for the first Swedish
OLIN survey15 in 1985 from a revised version16 of the British
Medical Research council questionnaire.17
Definitions
Ever asthma refers to the question “Have you ever had
asthma?” and physician-diagnosed asthma to “Have you
been diagnosed as having asthma by a doctor?”
Allergic rhinoconjunctivitis refers to “Have you had
allergic eye or nose symptoms (hay fever)?”
Asthma medication: “Do you currently use asthma
medicines (permanently or as needed)?”
Any wheeze: “Have you had wheezing or whistling in the
chest at any time in the last 12 months?”
Recurrent wheeze: “Do you usually have wheezing or
whistling in your chest when breathing?”
Longstanding cough: “Have you had longstanding cough
during recent years?”
Table 1 Study subjects by gender (M, men; W, women), age group, and smoking category.
M W M W M W M W M W M W
Age in 2007 31e40 41e50 51e60 61e70 71e80 Total
Invited (n) 516 762 603 768 548 724 377 530 266 390 2310 3174
Participated n 319 553 445 609 420 585 354 515 207 295 1745 2557
Participated (%) 62 73 74 79 77 81 94 97 78 76 76 81
Smokers 1996 (%) 37 34 42 33 31 33 36 23 21 14 35 29
Smokers 2007 (%) 32 21 33 24 24 25 29 18 12 9 27 21
Non-smoker 2007 (%) 48 57 41 51 36 44 31 55 42 70 39 54
Quitters 1996e07 (%) 13 15 12 10 10 8 8 7 10 5 10 9
Starters 1996e07 (%) 8 3 4 2 4 2 2 2 2 <1 4 2
Table 2 Prevalence of asthma, allergic rhinoconjunctivi-
tis, and respiratory symptoms in 1996 and 2007.
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(intermittent breathlessness) or attacks of breathlessness?”
with a further question about having had these symptoms
during the previous year.
Current smoking refers to those currently or within one
year having been smoking cigarettes, pipe or cigars.
Ex-smokers are those who quit smoking at least one year
previously.
Quitters smoked in 1996, but were ex- or non-smokers in
2007.
Starters were ex- or non-smokers in 1996, but smokers in
2007.
Countryside/farm living refers to those who lived in the
countryside/on a farm during the first 5 years of life.
Family history of asthma refers to those, whose parents,
sisters or brothers have asthma.
Family history of allergic rhinoconjunctivitis refers to
those, whose parents, sisters or brothers have allergic
rhinoconjunctivitis.
Crude cumulative incidence of asthma was calculated by
excluding from the population at risk those with either
physician-diagnosed asthma or ever asthma in 1996, and
calculating the proportion of new cases of physician-
diagnosed asthma in 2007.
Cumulative incidence of allergic rhinoconjunctivitis was
calculated by excluding from the population at risk those
with the condition in 1996, and calculating new cases in
2007.
Remission of asthma refers to those with physician-
diagnosed asthma and either use of asthma medication or
symptoms of shortness of breath during the previous year or
recurrent wheeze in 1996, but without these symptoms and
medication in 2007.
Remission of allergic rhinoconjunctivitis refers to those
who reported allergic rhinoconjunctivitis in 1996, but no
longer in 2007.Condition 1996 2007
(%) (%)
Physician-diagnosed asthma 6.8 9.4
Asthma medication use 6.1 9.8
Allergic rhinoconjunctivitis 38.0 40.8
Longstanding cough 19.8 19.1
Recurrent wheeze 6.7 6.9
Any wheeze 20.0 18.1
Shortness of breath 13.2 14.8Statistical analyses
Statistical analyses were performed with SPSS 15.0, with
the chi-square test for bivariate comparisons. Determinants
for incident cases of asthma were calculated by multiple
logistic regression. These analyses were performed with
age group, gender, family history of asthma, allergic rhi-
noconjunctivitis and smoking categories serving as inde-
pendent variables. Age group, gender, and family history ofallergic rhinoconjunctivitis served as covariates in calcula-
tion of risk factors for incident allergic rhinoconjunctivitis.
Multiple logistic regression analysis was used because there
was no information of time of events. The incidence rate
was assumed to be linear and was calculated using the
formula: a/(11  (b(a/2))) where a is the incident cases
and b the subjects at risk in 1996. Adjusted cumulative
incidence of asthma was calculated after excluding from
the population at risk besides those with asthma, also
subjects on asthma medication and those who reported
physician-diagnosed chronic bronchitis or COPD in 1996.
Further adjustment also excluded those reporting recurrent
wheeze or shortness of breath during the previous year at
baseline in 1996. Crude and adjusted incident rate ratios
(IRR) by gender were calculated, and a p-value <0.05 and
a 95% confidence interval were considered significant.ResultsRespiratory symptoms and smoking habits
Prevalence of asthma, use of asthma medication, and
allergic rhinoconjunctivitis had increased in the cohort
from 1996 to 2007, but there was no trend toward any
increase in asthma-related symptoms (Table 2). Of all
subjects reporting physician-diagnosed asthma in 2007,
allergic rhinoconjunctivitis was reported by 78.5%. Current
smoking decreased from 31.3% in 1996 to 23.3% in 2007.
Smoking decreased in both genders but remained more
common in men (p < 0.001). Smoking decreased less among
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25.6%.
Incidence
Totally 157 new asthma cases occurred from 1996 to 2007
corresponding to an incidence rate of 3.7/1000/year and
a cumulative 11-year total incidence of 4.0%, 4.6% among
women and 3.1% among men (p Z 0.014). The adjusted
cumulative 11-year incidence based on 132 asthma cases,
decreased to 3.5%, corresponding to 3.2/1000/year (women
3.7/1000/year; men 2.5/1000/year, p Z 0.026) with those
who used asthma medication and those with physician-
diagnosed chronic bronchitis or COPD at baseline
excluded. After further excluding those with recurrent
wheeze and shortness of breath at baseline from the pop-
ulation at risk, the incidence rate decreased to 2.5/1000/
year (Fig. 1).
Of these 132 new asthmatics, defined after excluding
those with asthma medication and chronic bronchitis or
COPD at baseline, shortness of breath during the previous
year was reported by 74.2%, any wheeze by 56.8%, recur-
rent wheeze by 28.0%, and longstanding cough by 44.7%.
Allergic rhinoconjunctivitis was reported by 65.2% of them;
78.0% used asthma medication, and 24.2% were current
smokers.
The incident cases of allergic rhinoconjunctivitis from
1996 to 2007 amounted to 447 (173 men; 274 women), with
a significantly higher incidence in women (pZ 0.012). This
corresponds to an 11-year cumulative incidence of 16.9%
and an incidence rate of 16.8/1000/year (Fig. 1). The
highest cumulative incidence of allergic rhinoconjunctivi-
tis, 23.0%, appeared in the youngest age group, with
a decreasing trend with increasing age: 18.8% in age group
41e50 years, 15.7% among those aged 51e60; 12.9%
between ages 61e70, and 13.8% among those 71e80 years
of age (p < 0.001). Incidence of allergic rhinoconjunctivitis
was 25.9% among those with a family history of allergic
rhinoconjunctivitis, and 14.5% among those withoutFigure 1 Annual incidence rate (cases/1000/year) of asthma
(AB) and allergic rhinoconjunctivitis by gender and difference
(p-value) by gender. Adjustment 1 excluded from population at
risk at baseline in 1996 besides asthmatics also those on asthma
medication and those with physician-diagnosed chronic bron-
chitis or COPD. Adjustment 2 further excluded also those
reporting in 1996 recurrent wheeze or shortness of breath
during the previous year.a family history (p < 0.001). Smoking was not associated
with incident allergic rhinoconjunctivitis. Incidence of
allergic rhinoconjunctivitis was significantly lower among
those who had lived in the countryside or on a farm during
the first 5 years of life compared to those who had not
(Fig. 2), while this was not true for asthma. Of those with
physician-diagnosed asthma but not allergic rhino-
conjunctivitis in 1996, 30.4% developed allergic rhino-
conjunctivitis over the following 11 years.
Allergic rhinoconjunctivitis and family history of asthma
were both significantly associated with incident asthma
(Table 3). Men reporting allergic rhinoconjunctivitis had
a 3- to 4-fold higher incidence of asthma than did men
without, whereas this effect was less than 2-fold among
women. In men, those with a family history of asthma had
a 3-fold incidence of asthma, and in women a 2-fold,
compared to those without asthma in the family. Gender,
smoking habits, and age group were also significantly
associated with incident asthma in univariate analyses.
Remission
Active asthma with current medication or symptoms
(shortness of breath during the previous year or recurrent
wheeze) was reported by 254 subjects (87 men; 167
women) in 1996. Of these, 43 (17%) were in remission in
2007 with no current use of medication or current symp-
toms (11 (13%) men; 32 (19%) women, pZ 0.189). A greater
proportion of those with asthma in remission had quitted
smoking between 1996 and 2007 than those with persistent
active asthma, 31% and 27%, respectively (ns). Remission of
allergic rhinoconjunctivitis occurred in 296 subjects, cor-
responding to a cumulative remission over 11 years of 18.1%
(men 20.6%; women 16.7%, p Z 0.06).
Multivariate analyses
Women were at higher risk for incident asthma than were
men (Table 4). Allergic rhinoconjunctivitis doubled the riskFigure 2 Cumulative incidence (%) of allergic rhino-
conjunctivitis over 11 years by farm and countryside living
during the first 5 years of life.
Table 3 Cumulative incidence of asthma (AB) with IRRs (95% CI) based on univariate analyses by allergic rhinoconjunctivitis
(ARC) in 1996, family history of asthma, and smoking categories.
Subjects Incident asthmaa Asthma excluding COPD and AB medication usersb
Subjects
at risk
1996 (n)
Cases
2007 (n)
Cumulative
incidence (%)
1996e2007
IRR (95% CI) Subjects at
risk 1996 (n)
Cases
2007 (n)
Cumulative
incidence (%)
1996e2007
IRR (95% CI)
ARC 1996
Men
No 1125 20 1.78 1 1099 16 1.46 1
Yes 501 30 5.99 3.36 (1.91e5.92) 476 26 5.46 3.74 (2.01e6.97)
Women
No 1449 53 3.66 1 1414 47 3.32 1
Yes 886 54 6.09 1.67 (1.14e2.44) 832 43 5.17 1.56 (1.03e2.36)
Fam.hist. of AB
Men
No 1393 33 2.37 1 1350 27 2.00 1
Yes 220 15 6.82 2.88 (1.56e5.30) 213 14 6.57 3.29 (1.73e6.27)
Women
No 1867 71 3.80 1 1801 61 3.39 1
Yes 445 35 7.87 2.07 (1.38e3.10) 426 29 6.81 2.01 (1.29e3.13)
Smoking 1996
Men
Non-smoker 708 10 1.41 1 699 9 1.29 1
Ex-smoker 360 18 5.00 3.55 (1.64e7.69) 353 17 4.82 3.74 (1.67e8.39)
Smoker 554 21 3.79 2.69 (1.43e5.05) 520 16 3.08 2.39 (1.06e5.41)
Women
Non-smoker 1320 45 3.41 1 1285 38 2.96 1
Ex-smoker 329 24 7.29 2.14 (1.30e3.51) 309 19 6.15 2.08 (1.20e3.61)
Smoker 681 38 5.58 1.64 (1.06e2.53) 647 33 5.10 1.72 (1.08e2.74)
a Subjects reporting physician-diagnosed asthma or ever asthma were excluded from the population at risk.
b Subjects with physician-diagnosed asthma, ever asthma, physician-diagnosed chronic bronchitis or chronic obstructive pulmonary
disease, and users of asthma medication in 1996 were excluded from the population at risk. IRRZ incidence rate ratio. CIZ confidence
interval.
Table 4 Risks in odds ratios (OR) with 95% confidence intervals (CI) for incidence of asthma (AB) by multiple logistic regression
analysis.
Independent variables Dependent variables
Variables Categories Incident asthmaa OR (95%CI) Asthma excluding COPD and AB
medication usersb OR (95%CI)
Age 31e40 1 1
41e50 0.96 (0.55e1.68) 0.90 (0.50e1.62)
51e60 1.20 (0.70e2.07) 1.12 (0.63e1.98)
61e70 1.55 (0.91e2.66) 1.43 (0.81e2.53)
71e80 2.33 (1.30e4.18) 2.41 (1.31e4.43)
Gender Men 1 1
Women 1.53 (1.07e2.20) 1.59 (1.08e2.34)
Family history of asthma No 1 1
Yes 2.05 (1.42e2.95) 2.19 (1.49e3.22)
History of allergic
rhinoconjunctivitis
No 1 1
Yes 2.15 (1.54e3.02) 2.00 (1.40e2.87)
Smoking habits 1996 Non-smoker 1 1
Ex-smoker 2.25 (1.45e3.48) 2.50 (1.58e3.96)
Smoker 2.00 (1.35e2.96) 2.06 (1.35e3.16)
a Subjects reporting physician-diagnosed asthma or ever asthma excluded from the population at risk.
b Subjects with physician-diagnosed asthma, ever asthma, physician-diagnosed chronic bronchitis or chronic obstructive pulmonary
disease, and users of asthma medication in 1996 excluded from the population at risk.
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being an ex-smoker or a current smoker also doubled the
risk for incident asthma in both models.
The results were similar when the multivariate analyses
were performed without allergic rhinoconjunctivitis in the
model; Having a family history of asthma yielded an OR 2.28
(95%CI 1.63e3.20) for incident asthma, with an OR 2.41 (95%
CI 1.65e3.52) after excluding those with asthma medication
and physician-diagnosed chronic bronchitis or COPD at
baseline. When family history of asthma was excluded from
the model, the magnitude of allergic rhinoconjunctivitis as
a risk for incident asthma remained similar, OR 2.13 (95%CI
1.57e2.90), and after exclusion of users of asthma medica-
tion and COPD from population at risk: OR 1.97 (95%CI
1.31e2.96).
Having a family history of allergic rhinoconjunctivitis
was a significant risk factor for incident allergic rhino-
conjunctivitis, OR 1.73 (95%CI 1.34e2.25). Farm living
during the first 5 years of life was protective for incident
allergic rhinoconjunctivitis, OR 0.75 (95% CI 0.57e0.99). In
multivariate analysis, the effect of gender and age did not
reach statistical significance.Discussion
A high incidence of allergic rhinoconjunctivitis was evident
in this 11-year survey, whereas incidence of asthma
remained at the same level as in recent studies performed
in neighboring countries and in Finland.4,5,7e9 The annual
incidence of rhinoconjunctivitis was 16.8/1000/year and of
asthma 2.5 to 3.7/1000/year depending on the criteria of
population at risk, both significantly higher for women than
for men. The prevalence of allergic rhinoconjunctivitis in
the cohort increased slightly from 38.0% to 40.9% between
1996 and 2007. Allergic rhinoconjunctivitis was an inde-
pendent risk factor for incident asthma, doubling the risk
for asthma consistently in different models of analysis.
The advantage of our study is the longitudinal follow-up
of a population based cohort. The original study population
was a representative sample of the general adult pop-
ulation of Helsinki.14 The participation rate, 76%, initially
obtained in the baseline survey in 1996 was good, with
a participation in 2007 even better, 78%, suggesting that
the results are representative. A possible bias in question-
naire studies is reliability of the responses. The question-
naire used has been validated in the Swedish OLIN
studies.7,18 Similar questions on ever asthma and physician-
diagnosed asthma in another Finnish study yielded a good
positive predictive value and a high specificity.19 Because of
the possibility of some misclassification of COPD as asthma,
we also calculated the adjusted incidence of asthma
excluding those with chronic bronchitis or COPD from the
population at risk, and also those on asthma medication at
baseline. Diagnosis of allergic rhinoconjunctivitis based on
self-reported symptoms may have led to some over-
estimation of the condition, but use of the same questions
in the follow-up survey allows assessment of the incidence
in the large cohort.
The prevalence of symptoms common in asthma remained
on similar level in the follow-up survey, but an increase in the
cohort occurred in prevalence of physician-diagnosedasthma and to some extent allergic rhinoconjunctivitis.
Current smoking decreased markedly, which was likely to
have contributed to the lack of increase of respiratory
symptoms despite of increasing age. The national Asthma
Programme 1994e2004 probably facilitated diagnostic
activity for asthma in Finland, which may at least partly
explain the increase in prevalence of asthma in the cohort.
During this time period also the ratio of defined daily doses
(DDD) of preventive asthma medication exceeded the use of
asthma relievers and the proportion of moderate and severe
asthma decreased.1,20 A high goal set in the Allergy Pro-
gramme was to reduce asthma and allergic rhinitis preva-
lence by 20% in 10 years, by 2018.6
The incidence of asthma ranged from 2.5 to 3.7/1000/
year depending on how the population at risk was defined.
The incidence was highest when only those with asthma at
baseline were excluded. It is a common practice to exclude
those with suspected asthma from the population at risk,
e.g., those on asthma medication or with asthma-related
symptoms at baseline. However, as COPD with some
reversibility of airway obstruction may be misdiagnosed as
asthma, it is reasonable to exclude also subjects with COPD
from the population at risk. Furthermore, in Finland, it is
more favorable for the patient to have a diagnosis of
asthma than of COPD, because with an asthma diagnosis
reimbursement for inhaled medication is much easier to
obtain. Reimbursement for asthma requires reversible
obstruction, but for COPD a severe obstruction is required,
which may lead to favoring asthma diagnosis. Possible
misclassification of COPD to asthma may have contributed
to the higher incidence of asthma in older age groups,
however, data from the Allergy Programme show that
incidence of persistent asthma among adults is highest
among those aged 70e79 years in Finland.20
The incidence of asthma in our study was similar to that
in recent reports from Sweden,7e9 but slightly higher than
in earlier Finnish studies.2,3 Our incidence was close to that
reported by Karjalainen et al. from Finland in 2001, with
1.65/1000/year for men and 2.47/1000/year for women.5
However, prospective population studies generally result
in somewhat higher estimates of incidence than do register
based studies or retrospective estimates of incidence.21,22
The study by Karjalainen et al had a large follow-up
cohort including nearly 50,000 incident cases of asthma,
as it pooled data from national registers for reimbursement
of asthma medication and occupational diseases based on
diagnoses reported by physicians. A linear increase in
asthmatic patients receiving special reimbursement for
asthma medication was obvious from the beginning of the
80s until the end of the 90s, probably reflecting an increase
in asthma prevalence.1 Whether a real plateau has been
reached remains to be verified. In many European coun-
tries, no further increase in asthma prevalence has been
noticeable since the about 1990.8,23,24
Remission of asthma occurred in 17% during the 11-year
follow-up, consistent with recent findings from Stockholm,
Sweden, with 15% remission in 10 years,8 but somewhat
higher than in the OLIN studies from northern Sweden.12,25
OLIN studies associated remission with previously mild
disease and cessation of smoking. The decrease in smoking
found in our study and the earlier reported decrease in the
proportion of moderate to severe asthma in Finland have
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asthma, possibly together with the increase in preventive
asthma medication use.1
The incidence of allergic rhinoconjunctivitis was higher
than in earlier Finnish studies.2,4 Our question combines
nasal and ocular symptoms, which may result in an increase
in positive responses. Some questionnaires assess for
rhinitis symptoms without including ocular symptoms. Use
of such a questionnaire led to a prevalence similar to ours
for allergic rhinitis, 37%.26 Remission of allergic rhino-
conjunctivitis was somewhat lower than in Sweden some
years ago, 23% in 8 years.27 The responses in our study
reflect, besides allergic rhinitis, also non-allergic rhinitis,
their symptoms being similar. Both forms of rhinitis were
significant risk factors for incident asthma in a recent
report of the ECRHS,10 one of the few longitudinal studies
assessing the impact of allergic rhinitis on risk for devel-
oping asthma.2,28 Our finding of 2-fold risk for incident
asthma among those with allergic rhinoconjunctivitis was
consistent with these findings. We found a lower incidence
of allergic rhinoconjunctivitis among those who had lived in
the countryside or on a farm during the first 5 years of life,
which confirms similar results of a recent study from
Sweden.29 This association remained in the multivariate
setting for farm living.
In multivariate analyses, both allergic rhinoconjunctivi-
tis and smoking were, besides genetic factors, highlighted
as risk factors for incident asthma. The effect of smoking
was stronger and that of genetic factors weaker in our study
than in Sweden.8 This may be explained by differences in
smoking habits between the countries; overall smoking was
more common in Finland and further, there were more
heavy smokers in Finland, thus contributing to a greater
extent to new onset of asthma. That former smoking was
a stronger risk factor for asthma is consistent with earlier
findings.30 Family history of allergic rhinoconjunctivitis
nearly doubled the risk for incident allergic rhino-
conjunctivitis, which reflects the importance of genetic
predisposition in allergic diseases. On the other hand,
allergic rhinoconjunctivitis yielded a similar doubled risk
for incident asthma even with family history of asthma in
the analyses, underlining the independent and strong
effects of rhinitis on asthma.
The impact of allergic rhinitis on asthma is largely
acknowledged today, and guidelines stress the importance
of treating both for patient well being.13 The nasal and
bronchial mucosa share similar inflammatory changes in
allergic patients, but for an unknown reason, epithelial
shedding is more pronounced in the bronchi.31 Allergen-
specific immunotherapy for allergic rhinitis has the poten-
tial to prevent the onset of asthma in children.32 Being
common and affecting the health-related quality of life,
allergic rhinitis deserves more attention and resources in
health care.33
In conclusion, we found a high prevalence and a high
incidence of allergic rhinoconjunctivitis. Living on a farm in
childhood yielded a lower risk of having allergic rhino-
conjunctivitis. Incidence of asthma was similar to results
from recent studies in Sweden and other Scandinavian
countries. Allergic rhinoconjunctivitis was an important risk
factor for incident asthma of the same magnitude as having
a family history of asthma. More focus should be uponstudying allergic rhinitis, to assess whether optimal treat-
ment could reduce the burden of allergic rhinitis and
possibly prevent the onset of asthma.Conflict of interest
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